Biocon Ltd enters weight loss drug market amid expiring patents

livemint.com

Biocon Ltd is venturing into weight loss drugs as patents for medications like Saxenda are expiring. The company's generic liraglutide injectible has UK approval, with more peptide formulations in development. The anti-obesity market, expected to reach $100 billion by 2030, is attracting companies like Biocon, Sun Pharma, Dr. Reddy's, and Cipla. Novo Nordisk plans to introduce Wegovy and Ozempic in India by 2026.


With a significance score of 4.3, this news ranks in the top 3.6% of today's 29047 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers: